MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
Gadolinium deposition disease
Gadolinium retention
Gadolinium-based contrast agents
MR imaging contrast agent
Nephrogenic systemic fibrosis
Radiology safety
Journal
Magnetic resonance imaging clinics of North America
ISSN: 1557-9786
Titre abrégé: Magn Reson Imaging Clin N Am
Pays: United States
ID NLM: 9422762
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
3
8
2021
Statut:
ppublish
Résumé
Gadolinium (Gd)-based contrast agents (GBCAs) have revolutionized of MR imaging, enabling physicians to obtain life-saving medical information that often cannot be obtained with unenhanced MR imaging or other imaging modalities. Since regulatory approval in 1988, more than 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile. Recent evidence has demonstrated, however, that a small fraction of Gd is retained in human tissues. No direct correlation between Gd retention and clinical effects has been confirmed; however, a subset of patients have attributed various symptoms to GBCA exposure. This review details current knowledge regarding GBCA safety.
Identifiants
pubmed: 33040991
pii: S1064-9689(20)30038-6
doi: 10.1016/j.mric.2020.06.001
pii:
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-507Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure J.S. McDonald and R.J. McDonald report research grants with GE Healthcare. R.J. McDonald report research grants with Bracco Imaging. J.S. McDonald and R.J. McDonald serve as scientific advisors for GE Healthcare.